- Home
- FLGT vs LAB Comparison
FLGT vs LAB Comparison
Compare FLGT & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLGT
- LAB
- Stock Information
- Founded
- FLGT 2011
- LAB 1999
- Country
- FLGT United States
- LAB United States
- Employees
- FLGT N/A
- LAB N/A
- Industry
- FLGT Medical Specialities
- LAB Biotechnology: Laboratory Analytical Instruments
- Sector
- FLGT Health Care
- LAB Industrials
- Exchange
- FLGT Nasdaq
- LAB Nasdaq
- Market Cap
- FLGT 587.3M
- LAB 473.2M
- IPO Year
- FLGT 2016
- LAB 2011
- Fundamental
- Price
- FLGT $21.93
- LAB $1.28
- Analyst Decision
- FLGT Buy
- LAB Buy
- Analyst Count
- FLGT 3
- LAB 2
- Target Price
- FLGT $25.33
- LAB $2.50
- AVG Volume (30 Days)
- FLGT 298.2K
- LAB 1.2M
- Earning Date
- FLGT 08-01-2025
- LAB 08-11-2025
- Dividend Yield
- FLGT N/A
- LAB N/A
- EPS Growth
- FLGT N/A
- LAB N/A
- EPS
- FLGT N/A
- LAB N/A
- Revenue
- FLGT $303,223,000.00
- LAB $172,271,000.00
- Revenue This Year
- FLGT $15.19
- LAB N/A
- Revenue Next Year
- FLGT $10.58
- LAB N/A
- P/E Ratio
- FLGT N/A
- LAB N/A
- Revenue Growth
- FLGT 4.31
- LAB 76.33
- 52 Week Low
- FLGT $14.57
- LAB $0.92
- 52 Week High
- FLGT $23.56
- LAB $2.32
- Technical
- Relative Strength Index (RSI)
- FLGT 68.17
- LAB 52.74
- Support Level
- FLGT $21.27
- LAB $1.15
- Resistance Level
- FLGT $21.77
- LAB $1.35
- Average True Range (ATR)
- FLGT 0.58
- LAB 0.07
- MACD
- FLGT 0.05
- LAB 0.00
- Stochastic Oscillator
- FLGT 94.59
- LAB 75.00
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.